Hokkaido University · Medicine
Professor Yuichiro Fujieda's research lab focuses on the immunological and clinical aspects of systemic autoimmune diseases, particularly antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The lab investigates the pathogenesis, clinical heterogeneity, and prognostic factors of thrombotic and neuropsychiatric manifestations in these conditions, with an emphasis on identifying biomarkers and optimizing therapeutic strategies. Key research directions include the role of autoantibodies, immune cell activation, and the impact of treatments such as DAPT and immunosuppressants in managing complications like arterial thrombosis and reversible posterior leukoencephalopathy syndrome (RPLS).
Figures are computed from collected data and may differ slightly.
High prevalence of arterial thrombosis was noted in Japanese patients with APS. The profile of heterogeneous and complex clinical manifestations was substantiated in Japanese patients with APS.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by diverse organ damages resulting from various autoantibodies, such as antinuclear or anti-DNA antibodies. Neuropsychiatric lupus (NPSLE) refers to the neurological and psychiatric disorders complicated with SLE and can be challenging for physicians to manage. NPSLE has a broad spectrum and high heterogeneity of clinical phenotypes, including headaches, psychiatric symptoms and peripheral neuropathy. Additionally,
DAPT might be considered as an effective and safe option for the prophylaxis of recurrent arterial thrombosis in APS.
Using cluster analysis, we clarified the characteristics of the APS patients with the poorest prognosis. Risk factors for cardiovascular disease may further increase events in patients with APS.
To characterize reversible posterior leukoencephalopathy syndrome (RPLS) in systemic lupus erythematosus (SLE) in terms of treatments for resolution and its clinical course, we reviewed 28 cases of RPLS in SLE including our cases in view of the treatment. Of these, 15 cases improved with blood pressure control and 13 required immunosuppressive therapy for activity of SLE presenting neurological manifestations. Patients without immunosuppressants at onset of RPLS more frequently required immunosu
Elevated plasma PSEP levels were correlated with disease activity of SLE, suggesting inappropriate monocyte or neutrophil activation in the pathophysiology of SLE exacerbation.
Journal Article Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus Get access Yuichiro Fujieda, Yuichiro Fujieda Department of Medicine II, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan Correspondence to: Yuichiro Fujieda, Department of Medicine II, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan Tel. +81-11-7065915; Fax +81-11-
Glucocorticoid-induced hyperglycemia (GIH) is an important complication to be managed by rheumatologists as it can affect morbidity and mortality of patients. Before administration of glucocorticoids, risk for the development of GIH should be assessed in every patient. A meta-analysis identified male gender, older age, family history of diabetes mellitus, current smoking history, past history of hypertension, higher body mass index, higher fasting plasma glucose (PG) and higher hemoglobin A1c (H
Infectious disease with various presentations in systemic lupus erythematosus often resembles lupus flare. A 37-year-old woman presented with a swollen left index finger that had not resolved, despite 7 years of immunosuppressive treatment. MRI showed rice-body formation in the flexor tendon sheath and tenosynovectomy demonstrated chronic synovitis with epithelioid granuloma. A mycobacterial culture confirmed invasive mycobacterial tenosynovitis due to Mycobacterium chelonae. The patient was tre
Open papers in the app to read, cite, and organize with AI.
